Biogen (NASDAQ:BIIB) Given New $180.00 Price Target at Rothschild & Co Redburn

Biogen (NASDAQ:BIIB) had its price objective boosted by Rothschild & Co Redburn from $150.00 to $180.00 in a report released on Wednesday,MarketScreener reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. Rothschild & Co Redburn’s price objective points to a potential downside of 4.94% from the company’s current price.

Several other equities analysts also recently issued reports on BIIB. The Goldman Sachs Group restated a “buy” rating on shares of Biogen in a research note on Monday, February 9th. Argus upgraded Biogen to a “hold” rating in a research note on Thursday, April 9th. Tudor Pickering set a $201.00 price objective on Biogen in a research note on Monday, February 9th. TD Cowen raised their target price on shares of Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Finally, Citigroup cut their target price on shares of Biogen from $215.00 to $190.00 and set a “neutral” rating on the stock in a report on Monday, April 13th. Fourteen analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Biogen has a consensus rating of “Hold” and an average target price of $211.31.

Biogen Stock Down 0.4%

Shares of BIIB stock traded down $0.71 on Wednesday, reaching $189.36. 101,612 shares of the stock were exchanged, compared to its average volume of 1,317,769. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The business’s 50 day moving average price is $185.53 and its 200 day moving average price is $174.73. The company has a market capitalization of $27.79 billion, a price-to-earnings ratio of 21.50, a PEG ratio of 2.48 and a beta of 0.16. Biogen has a twelve month low of $115.25 and a twelve month high of $202.41.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company’s revenue was down 7.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, sell-side analysts expect that Biogen will post 15.82 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 2,660 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.18% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Convergence Investment Partners LLC acquired a new position in shares of Biogen in the third quarter valued at approximately $1,342,000. Caprock Group LLC acquired a new position in shares of Biogen in the third quarter valued at approximately $742,000. Leuthold Group LLC acquired a new position in shares of Biogen in the third quarter valued at approximately $3,294,000. Generali Investments Management Co LLC increased its holdings in shares of Biogen by 408.2% in the third quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company’s stock valued at $1,397,000 after purchasing an additional 8,008 shares during the period. Finally, CWM LLC increased its holdings in shares of Biogen by 36.4% in the third quarter. CWM LLC now owns 47,455 shares of the biotechnology company’s stock valued at $6,648,000 after purchasing an additional 12,673 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: UBS upgraded BIIB to Buy and raised its price target to $225, citing a string of near?term pipeline and commercial catalysts that could lift the stock into 2027 — this is a major buy?side endorsement likely driving investor optimism. UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?
• Positive Sentiment: Biogen secured Greater China rights to felzartamab (immune?disease asset), giving it broader commercial control as global Phase III programs progress — a deal that supports upside to future revenues in Asia. BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up
• Positive Sentiment: Jim Cramer said he’s “reopening the file” on Biogen on Mad Money after recent analyst coverage, which can spur retail interest and momentum trading. Jim Cramer Says “I Got to Reopen the File on Biogen”
• Positive Sentiment: Wolfe Research raised its FY?2027 EPS view (higher long?term earnings projection), signaling some sell?side confidence in Biogen’s multi?year earnings power even as near?term estimates shift.
• Neutral Sentiment: TipRanks/coverage pieces reiterate the UBS view that Biogen’s late?stage pipeline, the Apellis acquisition and valuation discount could support sizable upside — this echoes the UBS thesis but is largely confirmatory. Biogen: Underappreciated Late?Stage Pipeline, Apellis Acquisition, and Valuation Discount Support 25–50% Upside
• Neutral Sentiment: Coverage of a separate commercial/partnering deal (TJ Biopharma) attracted attention and volume — supportive for narrative but not yet material to financials. Biogen Zooms on Deal with TJ Biopharma
• Negative Sentiment: HSBC reiterated a Reduce rating with a $150 target and published below?consensus multi?year EPS scenarios — a clear bearish analyst voice that can cap upside and raise downside risk.
• Negative Sentiment: Wolfe Research trimmed its Q1?2026 EPS estimate (lower near?term quarter projection), which increases odds of a tougher near?term earnings print.
• Negative Sentiment: Several previews and opinion pieces warn of weaker near?term earnings or valuation concerns ahead of results (Zacks preview; “3 Reasons to Avoid” article), which can temper momentum heading into the report. Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline 3 Reasons to Avoid BIIB and 1 Stock to Buy Instead

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.